KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q4 2025 value amounting to 12.01%.

  • Alnylam Pharmaceuticals' EBIT Margin rose 297400.0% to 12.01% in Q4 2025 from the same period last year, while for Dec 2025 it was 15.92%, marking a year-over-year increase of 237900.0%. This contributed to the annual value of 13.51% for FY2025, which is 213700.0% up from last year.
  • Alnylam Pharmaceuticals' EBIT Margin amounted to 12.01% in Q4 2025, which was up 297400.0% from 29.46% recorded in Q3 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' EBIT Margin peaked at 60.26% during Q1 2025, and registered a low of 104.89% during Q1 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' EBIT Margin averaged around 35.16%, with its median value being 36.7% (2023).
  • In the last 5 years, Alnylam Pharmaceuticals' EBIT Margin skyrocketed by 1261200bps in 2023 and then crashed by -438500bps in 2024.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' EBIT Margin stood at 75.26% in 2021, then rose by 25bps to 56.3% in 2022, then skyrocketed by 53bps to 26.47% in 2023, then surged by 33bps to 17.73% in 2024, then skyrocketed by 168bps to 12.01% in 2025.
  • Its last three reported values are 12.01% in Q4 2025, 29.46% for Q3 2025, and 2.09% during Q2 2025.